Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
Top Story
•
May 4, 2026
•
0 Views
Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.
Source: https://feeds.feedburner.com/foxnews/latest - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
